hVIVO plc Directors' Dealings (9735J)
April 05 2018 - 7:00AM
UK Regulatory
TIDMHVO
RNS Number : 9735J
hVIVO plc
05 April 2018
For immediate release 12.00pm: 5 April 2018
HVIVO PLC
("hVIVO" or the "Company")
Directors' Dealings
hVIVO plc (AIM: HVO), a specialty biopharma company with
discovery and clinical testing capabilities, announces that
application has been made to AIM for the admission of 18,595 new
ordinary shares of 5.0p each in the Company (the "New Ordinary
Shares").
The New Ordinary Shares have been allotted pursuant to the
purchase by Jaime Ellertson (Non-Executive Chairman) and Jim
Winschel (Non-Executive Director) of new ordinary shares, under the
terms of their letters of appointment as set out in the Company's
announcement of 4 November 2014 which stated that Mr Ellertson and
Mr Winschel had entered into binding commitments to purchase
$20,000 and GBP4,000 of hVIVO plc new ordinary shares respectively
per quarter. On 7 June 2017 Jaime Ellertson volunteered to reduce
his Director's fee by 10% to $180k pa, then on 13 November 2017 his
role changed from Non-Executive Chairman to Non-Executive Director
and his Director's fee reduced to GBP50k pa. His quarterly purchase
of shares has reduced accordingly as 40% of his Director's fee.
The New Ordinary Shares represent their investments for the
quarter ended 31 March 2018. On 4 April 2018, Mr Ellertson invested
in an additional 10,331 ordinary shares and Mr Winschel invested in
an additional 8,264 ordinary shares, at a price of 48.4 pence per
share.
Following admission of the New Ordinary Shares to trading on
AIM, the total number of ordinary shares with voting rights in
issue will be 78,216,137 and this figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
Admission of the New Ordinary Shares ("Admission"), which will
rank pari passu in all respects with the Company's existing shares
in issue, is expected to occur on 9 April 2018. Following
Admission, Mr Ellertson and Mr Winschel will be interested in a
total of 139,145 and 65,661 ordinary shares of 5.0p in the Company
respectively, representing 0.2% and less than 0.1% of the Company's
issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the persons discharging managerial responsibilities/persons
closely associated
a) Name Jaime Ellertson and Jim Winschel
-------------------------- ---------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/ Non-Executive Director
status
-------------------------- ---------------------------------------------
b) Initial notification/ Initial Notification
Amendment
-------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name hVIVO plc
-------------------------- ---------------------------------------------
b) Legal Entity N/A
Identifier
-------------------------- ---------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description Ordinary shares of 5 pence each
of the financial
instrument,
type of instrument GB00B6ZM0X53
Identification
code
-------------------------- ---------------------------------------------
b) Nature of Acquisition of ordinary shares
the transaction
-------------------------- ---------------------------------------------
c) Currency GBP
-------------------------- ---------------------------------------------
d) Price(s) and Director Price (p) Volume
volume(s) Jaime Ellertson 48.4 10,331
---------- -------
Jim Winschel 48.4 8,264
---------- -------
--------------------------
e) Aggregated
information
- Aggregated
volume
- Price 18,595
- Aggregated 48.4p
total
GBP8,999.98
-------------------------- ---------------------------------------------
f) Date of the 4 April 2018
transaction
-------------------------- ---------------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
-------------------------- ---------------------------------------------
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial &
Business Officer)
Media Enquiries +1 919 710 9658
Susan Flood (Head of Marketing)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Michael Burke (Corporate
Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell
(UK) +44 203 727 1000
John Capodanno / Evan Smith (US) +1 212 850 5705
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based analytical
platform to accelerate drug discovery and development in
respiratory and infectious diseases. Leveraging human disease
models in flu, RSV and asthma exacerbation, the hVIVO platform
captures disease in motion, illuminating the entire disease life
cycle from healthy to sick and back to health. Based in the UK,
market leader hVIVO has conducted more than 50 clinical studies,
inoculated over 2500 volunteers and has three first-in-class
therapies currently in development with a growing pre-clinical
pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUGURCCUPRGUA
(END) Dow Jones Newswires
April 05, 2018 07:00 ET (11:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2023 to Apr 2024